Abcuro is developing breakthrough therapies for autoimmune diseases and cancer, focusing on selective targeting of highly cytotoxic T cells
Abcuro is developing breakthrough therapies for autoimmune diseases and cancer, focusing on selective targeting of highly cytotoxic T cells. Their lead product candidate, ulviprubart, is a monoclonal antibody aimed at treating conditions such as inclusion body myositis and T cell lymphomas.